ZIMMER BIOMET HOLDINGS, INC.

Zimmer Biomet's capital structure is supported by a total equity of $12.7 billion and total liabilities of $10.4 billion, with a debt-to-equity ratio of 0.59. The company maintains a current ratio of 1.98, indicating a strong short-term liquidity position. Free cash flow of $1.47 billion in FY2025 supports operational flexibility, while cash and equivalents of $591.9 million provide a buffer against short-term obligations. Profitability metrics show a return on equity (ROE) of 5.55% and a return on assets (ROA) of 3.05%. These figures are below the industry median for ROE and ROA in the Medical Equipment, Supplies & Distribution sector, suggesting that Zimmer Biomet is underperforming in terms of capital efficiency and asset utilization. The company operates in three geographic segments: Americas, EMEA, and Asia Pacific. Revenue concentration is not explicitly disclosed, but the Americas segment is typically the largest contributor in the industry. Zimmer Biomet's exposure to EMEA and Asia Pacific may be subject to currency fluctuations and regulatory changes, which could impact its global revenue stability. Zimmer Biomet's growth trajectory is expected to remain stable, with no significant revenue acceleration or contraction in the near term. The company's focus on orthopedic robotics and digital solutions positions it for long-term innovation, but short-term growth is likely to be driven by market share retention and product portfolio rationalization. Risk factors include medium liquidity and dilution risk, with net cash being negative after subtracting total debt. The company has disclosed potential dilution from future offerings or ATM programs, and its restructuring and integration plans could introduce operational and financial volatility. The risk assessment also highlights the potential for supply chain disruptions and cybersecurity threats. Recent filings include forward-looking statements about sales and earnings guidance, as well as risks related to competition, pricing pressures, and the transformation of its sales and distribution network. The company also disclosed the impact of healthcare reform and cost containment measures on its business.